News release

Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform

Production Department Senior Manager wins “8th Annual Achievement Award for the Development of Female Technologists”

Supporting the Early Commercialization of Regenerative Medicine for Corneal Endothelium

— Partial Product Development Contract with ActualEyes Inc. —

Toward creation of a database for results of skin irritation tests using an alternative to animal testing

– With a grant from JSAAE, 6 corporations continue contributing jointly to the cosmetics industry –

Re-examination of Autologous Cultured Cartilage “JACC”

J-TEC announces application for marketing approval for stable vitiligo treatment: Autologous Cultured Epidermis "ACE02"

The research group from Jikei University School of Medicine and St. Marianna University School of Medicine launched an investigator-initiated clinical trial of autologous nasal mucosal epithelial cell sheets for middle ear cholesteatoma

— J-TEC commissioned with contract manufacture of the IP —

10th Technology and Management/Innovation Award “METI Minister's Award” Winner

“Popularization of Japan’s First Regenerative Medical Product – Autologous Cultured Epidermis JACE”

Announcement of Start of Clinical Trial for Allogeneic Cultured Epidermis “Allo-JaCE03”

- J-TEC’s first allogeneic cell therapy product: Submitted notification of clinical trial plan to realize ready-made product that can be swiftly provided to patients -

Announcing approval of Autologous Cultured Oral Mucosal Epithelium “Ocural” for NHI listing

Listing effective December 1 creates new option for treatment of bilateral limbal stem cell deficiency

Announcement : Acceptance of Development Project in FY2021 AMED Program for the Promotion of Innovation through Industrial-Academic Collaboration

Marketing approval obtained for Autologous Cultured Oral Mucosal Epithelium “Ocural”

— World’s first regenerative medical product using oral mucosal epithelial cells for the treatment of limbal stem cell deficiency —

Reviewed and acknowledged by MHLW subcommittee: approval of autologous cultured oral mucosal epithelial cell sheet (development code: COMET01)

Change in Parent Company from Fujifilm Corporation to Teijin Limited.

Towards the Creation of Novel Regenerative Medical Products in the Field of Ophthalmology Marketing Approval Application for Autologous Cultured Oral Mucosal Epithelium (Development Name: COMET01)

Providing new treatment options with Japan’s first regenerative medical product in ophthalmology field Obtained marketing approval for autologous cultured corneal epithelium "Nepic"

Skin Corrosion Testing Method using "LabCyte EPI-MODEL24" Human 3-Dimensional Cultured Epidermis Included in OECD Test Guideline.

Announcement of Application for Manufacturing and Marketing Approval for Cultured Autologous Corneal Epithelium (Development name: EYE-01M)

- First application for a regenerative medical product in the field of ophthalmology in Japan -

Expansion of Indication for Autologous Cultured Epidermis “JACE”: Dystrophic and Junctional Epidermolysis Bullosa

Toward Expansion of Indication to Include Secondary Knee Osteoarthritis from Trauma, Etc. Submission of CTN for Clinical Trial of Autologous Cultured Cartilage “JACC”

Eye Irritancy Testing Method using “LabCyte CORNEA-MODEL24” Human 3-Dimensional Cultured Corneal Epithelium Included in OECD Test Guideline

Submission of CTN for Clinical Trial of Autologous Cultured Epidermis with Melanocyte, “ACE02” for the Treatment of Leukoderma

Japan Tissue Engineering, Nagoya University, and Shinshu University sign patent license agreement for the development of a low-cost manufacturing technology for autologous CAR-T cell therapy with enhanced targeting efficiency against CD 19-positive acute lymphoblastic leukemia

Notification of the passing of Dr. Howard Green

Japan Tissue Engineering provides support to rescue victims of Taiwan water park explosion Autologous cultured epidermis JACE® treatment for severe burn victims

Notice Regarding Change in President and CEO

Notice Concerning Change in Parent Company

Notification Regarding the Exercise of Subscription Rights Through Private Allocation to a Third Party

Started multicenter clinical trials of autologous cultured corneal epithelium.

Awarded the 12th Award for Persons of Merit in Industry-Academia-Government Collaboration (Minister of Health, Labour and Welfare Prize).

Notice Concerning Issue of Subscription Rights Through Private Allocation

Awarded the 2013 Nikkei Superior Products and Services Awards: Nikkei Awards for Excellence.

Awarded the 5th MONOZUKURI Manufacturing Japan Grand Awards: Prime Minister’s Prize.

Introducing LabCyte CORNEA-MODEL

Autologous Cultured Cartilage “JACC”: Listed as an item covered by the National Health Insurance in Japan.

J-TEC Received Government Approval to Manufacture and Sell Autologous Cultured Cartilage JACC in Japan

Announcement: Opening of Singapore Representative Office

Announcement: Establishment of a Representative Office in Singapore

Announcement Rearding Issuance of New Shares by Third Party Allocation, and a Change in the Largest Shareholder

Announcement: J-TEC has submitted an application for manufacturing and sales of autologous cultured cartilage

On January 1 2009, J-TEC's autologous cultured epidermis "JACE" was listed as an item covered by the National Health Insurance in Japan.

J-TEC has received reimbursement approval for the autologous cultured epidermis "JACE" in Japan. The reimbursement will start in Janurary 2009.

J-TEC joined the Jasdaq Securities Exchange's Neo market for venture firms on December 21, 2007.

On October 29, 2007, J-TEC officially received government approval to culture and sell autologous cultured epidermis JACE for serious burns treatment in Japan.

J-TEC got the go-ahead by the health ministry panel of the Ministry of Health, Labor and Welfare, for the manufacturing & sales approval of cultured epidermis in Japan.

Awarded the highest prize in the New Business Awards 2006, sponsored by the Chubu Economic Federation.

J-TEC awarded the Japan Bioventure Grand Prize, the top honor in the 4th Japan Bioventure Grand Prize awards.

Started marketing of LabCyte

Awarded President of the Science Council of Japan's Award at the 16th Awards for Excellence in Collaboration Between Industry, Academia, and Government.

Obtained authorization to begin clinical trials of autologous cultured cartilage.

Started multicenter clinical trials of autologous cultured epidermis.

Japan Tissue Engineering Co., Ltd established.